456 Studies Now Enrolling
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701
Off the shelf T-cells therapy for viral infection post HCST
| Sponsor: | Pediatric Bone Marrow Transplant Consortium |
| Enrolling: | Male and Female Patients |
| Study Length: | 3 Years |
| IRB Number: | AAAR8071 |
| Contact: | Jean Sosna, RN: 212-305-2050 / js4403@cumc.columbia.edu |
Additional Study Information:
In this trial, we will evaluate whether partially-HLA matched allogeneic multivirus-specific VSTs, will be safe and produce anti-viral effects in immunodeficient recipients infected with one of more of the targeted viruses that are persistent despite conventional anti-viral therapy. This will be in patients who have received a hematopoietic stem cell transplant or patients with primary immunodeficiency conditions who have persistent viral infections and have not undergone HSCT.
This study is closed
Do You Qualify?
| Do you/your child have a HCST or a diagnosis of a primary immunodeficiency disorder? | Yes | No |
| Do you/your child have CMV, adenovirus and/or EBV infection? | Yes | No |
| Do you/your child have any other uncontrolled infections? | Yes | No |
| Do you/your child have a malignacy relapse (return)? | Yes | No |